Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Ann Intern Med. Author manuscript; available in PMC 2013 February 21.
Published in final edited form as:
PMCID: PMC3578600

Stool DNA Testing to Screen for Colorectal Cancer in the Medicare Population

A Cost-Effectiveness Analysis



Centers for Medicare and Medicaid Services (CMS) considered whether to reimburse stool DNA testing for colorectal cancer screening among Medicare enrollees.


To evaluate the conditions under which stool DNA testing could be cost-effective compared with the colorectal cancer screening tests currently reimbursed by CMS.


Comparative microsimulation modeling study using two independently-developed models.

Data Sources

Derived from literature.

Target Population

65-year-old (Medicare eligible) individuals; 50-year old individuals as sensitivity analysis.

Time Horizon



Third-party payer.


Stool DNA test every 3 or 5 years in comparison to currently-recommended colorectal cancer screening strategies.

Outcome Measures

Life expectancy, lifetime costs, incremental cost-effectiveness ratios, threshold costs.

Results of Base-Case Analysis

Assuming a cost of $350 per test, strategies of stool DNA testing every 3 or 5 years yielded fewer life-years and higher costs than the currently recommended colorectal cancer screening strategies.

Results of Threshold Analysis

Screening with the stool DNA test would be cost-effective at per-test cost of $40 to $60 for 3-yearly stool DNA testing, depending on the simulation model used. There were no levels of sensitivity and specificity for which stool DNA testing would be cost-effective at its current cost of $350 per test. Stool DNA testing at 3-yearly intervals would be cost-effective at a cost of $350 per test if the relative adherence with stool DNA testing were at least 50% better than with other screening tests.

Results of Sensitivity Analysis

None of the above mentioned results changed significantly when considering a 50-year old cohort.


We did not model other pathways than the traditional adenoma-carcinoma sequence.


Only if a significant reduction can be made to the test cost or if its availability would entice a large fraction of otherwise unscreened persons to be screened will stool DNA testing be a cost-effective alternative for colorectal cancer screening.

Primary Funding Source

Agency for Healthcare Research and Quality


Recently, new studies have been published on test performance characteristics of stool DNA testing for colorectal cancer screening.(12) Although the recent results by Ahlquist et al were not very promising with 20% and 46% sensitivity for screen-relevant neoplasms for two different stool DNA tests,(1) some believe that reasons for optimism remain.(3) Itzkowitz et al. validated a new marker for stool DNA testing and found a sensitivity of 83% for cancer (2) and further technological advances are expected for stool DNA testing. However, stool DNA testing should only be offered if it is both effective and cost-effective compared to the currently-recommended screening tests.

In August 2007, the Centers for Medicare and Medicaid Services (CMS) opened a National Coverage Determination (NCD) to determine whether a stool DNA test, PreGen-Plus™, should be covered as an option for colorectal cancer screening among average-risk Medicare enrollees on a national basis ( PreGen-Plus™ consists of a panel of 23 molecular markers associated with colorectal cancer. The test analyzes the DNA for 21 specific point alterations in the APC, K-ras and p53 genes, a marker for microsatellite instability known as BAT-26, and a novel marker known as DNA Integrity Assay (DIA®), all of which have been associated with the presence of cancer. In response to this NCD, 2 colorectal cancer modeling groups from the National Cancer Institute’s (NCI) Cancer Intervention and Surveillance Modeling Network (CISNET) were asked to perform a cost-effectiveness analysis of screening with this stool DNA test among the average-risk Medicare population. The objective was to identify the reimbursement rate at which this stool DNA test could be cost-effective compared with the colorectal cancer screening tests currently reimbursed by CMS.


We evaluated the cost-effectiveness of stool DNA testing using two existing independently-developed microsimulation models of the CISNET consortium: MISCAN (Microsimulation Screening Analysis, from Erasmus University Medical Center and Memorial Sloan-Kettering Cancer Center), and SimCRC (the Simulation Model of Colorectal Cancer, from the University of Minnesota and Massachusetts General Hospital).(47)

The Models

Appendix 1 describes the MISCAN and SimCRC models and standardized profiles of each model’s structure, underlying assumptions, and calibration methods are available at Briefly, each model simulates the life histories of a large population of individuals from birth to death and has a natural history component that tracks the progression of underlying colorectal disease in the absence of screening. As each simulated individual ages, there is a chance that one or more adenomas may develop depending on age, sex, race and individual risk. Adenomas can progress from small (≤5 mm) to medium (6–9 mm) to large (≥10 mm) size, and some may eventually become malignant. A preclinical cancer (i.e., not detected) has a chance of progressing through stages I to IV and may be detected by symptoms at any stage. With screening, adenomas and preclinical cancers may be detected depending on the sensitivity of the test for that lesion and, for endoscopic tests, whether the lesion is within reach of the endoscope.

The natural history model outcomes were calibrated to pre-screening data from autopsy studies (818) and clinical incidence data from the Surveillance, Epidemiology, and End-Results (SEER) Program before the introduction of screening (1975–1979).(19) The models use all-cause mortality estimates from the US life tables and colorectal cancer survival data from SEER (1996–1999). Both models have been validated against the long-term reductions in incidence and mortality of colorectal cancer with annual FOBT reported in the Minnesota Colon Cancer Control Study (2022) and show good concordance with the trial results. The outcomes predicted by the natural history models for individuals at age 65 are compared in Appendix 2.

Colorectal Cancer Screening Strategies

The National Coverage Determination requested that we evaluate the health effects and costs associated with stool DNA testing every 5 years. In the light of the similarities between FOBT and stool DNA screening we also evaluated a shorter interval of 3 years. We compared the health effects and costs of both strategies with those from the screening strategies currently covered by Medicare (23) and included in most colorectal cancer screening guidelines:(2427) annual FOBT; flexible sigmoidoscopy every 5 years; flexible sigmoidoscopy every 5 years in conjunction with annual and 3-yearly FOBT; and colonoscopy every 10 years. We considered 3 FOBTs (Hemoccult II, Hemoccult SENSA, and immunochemical FOBT) and 2 strategies for sigmoidoscopy (with and without biopsy). In the strategy of sigmoidoscopy with biopsy, all detected polyps are biopsied and only persons with an adenomatous polyp are referred for a follow-up colonoscopy. With sigmoidoscopy without biopsy, all patients with detected polyps are directly referred for colonoscopy. In our primary or “base-case” analysis, we assumed all individuals begin colorectal cancer screening at age 65 and stop at age 80.

Follow-up, Surveillance, and Adherence Assumptions

We assumed that an individual with a positive FOBT, sigmoidoscopy, or stool DNA test would be referred for follow-up colonoscopy and, if negative, would undergo subsequent screening with colonoscopy every 10 years. Individuals with adenomas that were detected and removed by colonoscopy (screening or diagnostic) were assumed to undergo colonoscopy surveillance per guidelines (i.e., every 3 years among individuals with an adenoma 10 mm or larger or with 3 or more adenomas of any size detected at the last colonoscopy, and every 5 years otherwise).(28) We assumed that surveillance continued until the diagnosis of colorectal cancer or death. For the base-case analysis, we assumed individuals were 100% adherent with the screening test of interest and with the recommended follow-up and surveillance; alternative adherence assumptions were explored in a sensitivity analysis.

Test Characteristics

Test characteristics were based on literature review (Table 1). For the stool DNA test, we used the sensitivity for cancer and specificity based on PreGen-Plus (version 1.1).(32) We used studies of the older version of the stool DNA test (version 1.0) to estimate the sensitivity of the test for detecting adenomas (2931) as the estimates were not available for version 1.1. We further assumed that adenomas smaller than 5 mm were not detectable by the stool DNA test, but could be detected as a false-positive result based on the lack of specificity of the test. Patients undergoing colonoscopy and sigmoidoscopy were assumed to be at risk of serious complications (Table 2). There are no complications from FOBT or stool DNA tests.

Table 1
Screening test characteristics and costs used in the analyses
Table 2
Model inputs for complication rates and costs, and colorectal cancer treatment costs


The base-case cost-effectiveness analysis was conducted from the CMS perspective. Screening test costs were based on Medicare payments in 2007 (Table 1).(46) For the stool DNA test, we used a private insurer reimbursement of $350 as a base case.(33) The costs of complications were based on the relevant diagnosis-related group codes.(46) (Table 2) Net costs of colorectal cancer-related care were obtained from an analysis of 1998–2003 SEER-Medicare linked data (47) (personal communication, Robin Yabroff, Ph.D. and Martin Brown, Ph.D) and were updated to 2007 dollars using the overall Consumer Price Index. Costs from that period do not reflect the use of the expensive monoclonal antibodies bevacizumab and cetuximab. The costs vary by stage at diagnosis and phase of care (Table 2).

Cost-Effectiveness Analysis

We used the simulation models to calculate the lifetime costs and life expectancy for a previously unscreened cohort of 65-year-old Medicare beneficiaries under 15 competing strategies, including no screening. We conducted an incremental cost-effectiveness analysis from the perspective of CMS and discounted future costs and life years 3% annually to account for time preferences for present over future outcomes.(48) Strategies that were more costly and less effective than another strategy were ruled out by strong dominance. Strategies that were more costly and less effective than a combination of other strategies were ruled out by weak dominance. The relative performance of the remaining strategies was measured using the incremental cost-effectiveness ratio (ICER), defined as the additional cost of a specific strategy, divided by its additional clinical benefit, compared with the next least expensive strategy. All non-dominated strategies represent the set of potentially cost-effective options (depending upon the willingness to pay for a life-year gained) and lie on the efficient frontier.

Threshold Analysis

If the stool DNA strategies were found to be dominated by the currently-reimbursed screening options, for each DNA tool strategy, we calculated the maximum cost per stool DNA test (i.e., the threshold cost) for that strategy to lie on the efficient frontier (i.e., be cost-effective). Second, because the stool DNA test is still evolving,(3) we identified the threshold stool DNA costs for scenarios in which the diagnostic performance of the stool DNA test was improved. The base-case estimates of the sensitivities for small, medium, and large adenomas and for cancer, as well as the estimate for specificity were increased by 10%, 25%, 50%, 75% and 100% of the difference between the base-case values and perfect sensitivity and specificity. Finally, since some have suggested that the availability of a stool DNA test as an option for colorectal cancer screening might entice a previously unscreened individual to undergo screening, we also identified threshold stool DNA costs for scenarios in which we allowed the adherence of stool DNA strategies to be greater than that of all other screening strategies. For this analysis we assumed an overall adherence rate of 57% for each test (i.e., the percent of Medicare-eligible individuals who were adherent with colorectal cancer screening recommendations in the 2005 National Health Interview Survey)(49) with this 57% of the population completely adherent to screening and the remainder completely non-adherent. Modeling adherence in this fashion allowed us to evaluate the impact of enhancing screening participation among a previously unscreened segment of the population. We varied the adherence for a stool DNA strategy from 57% to 100%. Subsequently, threshold costs for stool DNA were calculated comparing overall costs and life-years saved using stool DNA at these higher adherence rates to competing strategies at an adherence rate of 57%.

Sensitivity Analysis

To evaluate how the estimated stool DNA threshold costs were influenced by our assumptions, we also identified threshold costs in sensitivity analyses with alternative assumptions. First, we explored the effect of a screening interval of 1 year for stool DNA testing. Second, we considered alternative stool DNA test versions. We evaluated version 1.0 (the only stool DNA test that has been evaluated in a general population setting) (1, 29) and a newer version of the stool DNA test (version 2.0)(39) (see Table 1 for test characteristics).

Next, we repeated our base-case threshold analysis for a cohort of 50-year-olds with screening beginning at age 50 as recommended in colorectal cancer screening guidelines (2427). Finally, we conducted an analysis from a modified societal perspective by including direct costs borne by beneficiaries as well as patient time costs. We did not incorporate productivity costs. Cost inputs for the modified societal perspective are shown in Tables 1 and and22.

Role of the Funding Source

This research was supported by the Agency for Healthcare Research and Quality (HHSP233200700123P, HHSP233200700196P, HHSP233200700350P) and the NCI (U01-CA-088204, U01-CA-097426, and U01-CA-115953). The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, and approval of the manuscript.


In the absence of screening, the two models project that 57 out of every 1,000 65-year-old individuals will be diagnosed with colorectal cancer in their lifetimes (Table 3). With screening, many of these colorectal cancer cases can be prevented. Assuming 100% adherence, the reduction in the lifetime risk of colorectal cancer ranged from 32–40% with annual Hemoccult II screening to 53–72% with 10-yearly colonoscopy screening (the reported ranges reflect differences in projections by model). CRC risk reduction with stool DNA testing was similar to that of Hemoccult II and varied from 30–49% depending on the simulation model and the interval used.

Table 3
Undiscounted number of cases and deaths of colorectal cancer per 1000 65-year-olds, by screening scenario

Figure 1 shows a plot of total life-years gained (compared with no screening) and total lifetime direct medical costs from the Medicare perspective for each of the 18 screening strategies, and the efficient frontier: the economically rational subset of choices. Five-yearly stool DNA testing was the least effective of all evaluated screening strategies, while the 3-yearly strategy was only slightly more effective than annual Hemoccult II. Assuming reimbursement at $350 per test, both stool DNA testing strategies were the most expensive screening strategies, lying to the far right of the cost-efficient frontier. Although dominated by the currently-recommended screening options, the costs per life-year gained compared with no screening were less than $15,000 for both screening intervals and models (Appendix 3).

Figure 1Figure 1

Threshold Analyses

Threshold analyses indicated that to be cost-effective, the stool DNA test would need to cost between $34 and $51 when performed every 5 years, or between $40 and $60 when performed every 3 years, depending on the simulation model used. Analysis of 3-yearly and 5-yearly stool DNA testing with the SimCRC model identified no sensitivity and specificity estimates for which the threshold value of the cost of the stool DNA test could be greater than its base-case value of $350 and still lie on the efficient frontier (Figure 2). With the MISCAN model, the cost of the stool DNA test may rise to $364 if the test is perfect with respect to sensitivity and specificity and if offered every 5 years.

Figure 2
Stool DNA unit test cost thresholds at which the stool DNA strategies are efficient screening options compared with other reimbursed colorectal cancer screening strategies for different combinations of stool DNA test sensitivity and specificity. All sensitivities ...

Analyses with the MISCAN model showed that adherence with stool DNA testing has to be almost 50% better than with other tests for 3-yearly stool DNA testing to be on the frontier at the base-case cost of $350 (Figure 3). With the SimCRC model the relative adherence with stool DNA testing had to be between 50% and 75% better than adherence with other modalities for 3-yearly stool DNA testing to be on the frontier at the base-case cost of $350.

Figure 3
Stool DNA unit test cost thresholds at which the stool DNA strategies are efficient screening options compared with other reimbursed colorectal cancer screening strategies for different levels of adherence with stool DNA screening. Adherence for stool ...

Sensitivity Analyses

Offering DNA testing annually did not change the threshold costs ($40–$48). There was no threshold cost at which the stool DNA testing with version 1.0 could be a cost-effective alternative for colorectal cancer screening. For version 2.0 threshold costs were $2–$31, which are lower than the base-case threshold costs. Only from a modified societal perspective did the threshold costs of the stool DNA test (excluding co-payments and patient time costs) increase somewhat compared with the base-case estimate: $88–$134 for the 5-year interval and $73–$116 for the 3-year interval. The higher frequency of FOBT scenarios results in considerably higher additional time costs than with stool DNA screening, allowing for higher per-test costs for the stool DNA test.

None of the above mentioned results changed substantially when considering a 50-year old cohort instead of the 65-year old Medicare eligible cohort. The threshold costs would have to fall to $27–$52 for stool DNA testing to be on the efficient frontier.


Our analysis showed that 3- and 5-yearly stool DNA testing were both more costly and less effective than annual screening with a sensitive FOBT. Screening with a stool DNA test would be an efficient strategy at a per-test cost of $34–$60, depending on the screening interval (3 or 5 years) and model used. Only if the relative adherence with stool DNA testing were 50% better than other screening tests, would the test be cost-effective at current test costs. These results hold both for the Medicare-eligible population, as well as the general screening population. The fact that two independently-developed models come to similar conclusions with respect to cost-effectiveness and threshold costs of stool DNA screening shows the robustness of the results for model uncertainties, particularly pertaining to the natural history of colorectal disease.

We had anticipated that stool DNA testing would be dominated by screening with a sensitive FOBT given that the stool DNA test has similar sensitivity and specificity as Hemoccult SENSA with a cost that is almost 80 times greater. Consequently the aim of our analysis was to explore the conditions under which stool DNA testing could compete with the existing screening tests. We have only explored the potential of stool DNA testing for colorectal cancer screening. The test might also have prognostic or even treatment implications, for example through risk stratification based on genetic markers or by guiding the use of genomic-targeted therapies. However, in this case the test becomes a diagnostic tool that can be administered at the time of diagnosis of colorectal cancer rather than a pre-symptomatic screening test. The evaluation of the cost-effectiveness of a stool DNA test as a diagnostic test is beyond the scope of our analysis.

Because stool DNA testing is still evolving,(3) we evaluated threshold costs for improved test characteristics. Such improvements can be expected, given technological advances in the form of more sensitive polymerase chain reaction strategies.(3) However, the threshold costs for the latest published version of the stool DNA test (version 2.0),(39) are lower than the threshold costs for the base-case stool DNA test (version 1.1) due to the many unnecessary colonoscopies brought about by the considerably lower specificity. Even under the extreme assumption of perfect sensitivity and specificity, the threshold cost for the stool DNA test remained below $350 at intervals of 3 or 5 years.

Substantially higher adherence with stool DNA testing would make stool DNA screening cost-effective at $350. However, while it has been shown that the stool DNA test is acceptable to patients who have already agreed to participate in a screening program,(5152) there is no evidence that screening adherence with stool DNA testing would be substantially better than with other tests. Adherence needs to be 50% better than even FOBT and since both types of tests are non-invasive, this is unlikely. In the absence of this adherence benefit, stool DNA remains dominated.

Stool DNA testing is currently included in the American Cancer Society (ACS) guidelines for colorectal cancer screening (24). Twelve US states and the District of Columbia have legislative mandates requiring that certain insurers should offer all screening options of the current ACS guidelines. As a consequence, coverage of stool DNA screening is now mandated in these states.(53) For every 65-year-old person switching from Hemoccult SENSA or colonoscopy screening to stool DNA screening, colorectal cancer screening costs would increase on average by $750–$1250 (results not shown), while the life-years saved would on average decrease. In the US, there currently are 2.6 million 65-year olds,(54) so on a national level stool DNA screening could potentially lead to an unnecessary expenditure of $3 billion per year. These figures would be even higher, when considering the complete target population for screening from age 50.

Our findings are comparable to two published cost-effectiveness analysis of stool DNA screening.(5556) Like ours, both analyses concluded that the stool DNA test was dominated by currently recommended colorectal cancer screening tests. Wu et al. found threshold costs that were slightly higher ($57–$70) than the threshold costs in this analysis. However, those threshold costs were based on a willingness to pay of $13,000 per life-year gained compared to no screening. Song et al. found threshold costs of $195 when comparing 2-yearly stool DNA testing to 10-yearly colonoscopy and assuming considerably higher colonoscopy costs. A similar comparison in the MISCAN and SimCRC models yielded threshold costs of $205–$213.

There are several limitations of the models. First, the models simulate the progression from adenoma to colorectal cancer by increasing the size of the adenomas over time. Because adenoma size and the presence of villous components or high-grade dysplasia are highly correlated,(57) size indirectly represents histology and grade. However, neither model separately simulates the step from adenoma with low-grade dysplasia to an adenoma with high-grade dysplasia. If the advantage of a stool DNA test is detection of a smaller adenoma at the stage of high-grade dysplasia, we may underestimate its effectiveness. Second, we assumed that all colorectal cancers arise through the traditional adenoma-carcinoma sequence, with a linear sequence of mutations in the APC, KRAS and TP53 genes. Recent data indicate the probable existence of at least one alternative pathway to colorectal cancer through a mutation of the BRAF gene.(58) Existence of different pathways will probably not influence the performance of FOBT because bleeding of a lesion is unlikely to be related to the pathway. It may influence sensitivity of endoscopy, as lesions from this pathway are more likely to be proximal and sessile or flat and therefore more difficult to find. However for the stool DNA test, the lesion in question may have acquired a gene mutation not assessed by the test. In this case, a person with a false-negative result on such a test will have a higher than average probability of having a negative test with subsequent screens. Consequently, we may have overestimated the benefit and the threshold cost of this test.

In conclusion, our analysis shows that future developments of the stool DNA test should not only focus on improving test characteristics but also on reducing test cost. The first stool DNA assay that reached the market was expensive ($795); a more recent stool assay for vimentin methylation alone was introduced this year at a cost of $220.(3) These numbers offer hope that further technological refinements will permit significant cost reductions. We are currently lacking good information on the performance characteristics of these new tests. When the performance levels of newer versions of the stool DNA test become available, the results of our sensitivity analysis can be used to determine their cost-effectiveness. If the cost of the test is higher than the threshold costs associated with the level of performance of the new test, it will not be cost-effective. Our analysis shows, that improving tests characteristics alone is insufficient to make stool DNA testing cost-effective. Without further cost reductions, stool DNA screening will not be a cost-effective alternative for average-risk colorectal cancer screening in the Medicare population or the general screening population.

Reproducible Research Statement

Models are available to approved individuals with written agreement.

Supplementary Material



This research was supported by the Agency for Healthcare Research and Quality (AHRQ) (HHSP233200700123P, HHSP233200700196P, HHSP233200700350P) and the National Cancer Institute (U01-CA-088204, U01-CA-097426, and U01-CA-115953). The findings and conclusions in this article are those of the authors who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this article should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

We acknowledge Martin Brown, PhD and Robin Yabroff, PhD of the National Cancer Institute (NCI) for their assistance with obtaining cancer treatment costs using SEER-Medicare data; Joan Warren, PhD and Carrie Klabunde, PhD of NCI for sharing their preliminary analysis of SEER-Medicare data on colonoscopy-related complications; John Allen, MD of Minnesota Gastroenterology and Joel Brill, MD of Predictive Health for their assistance in deriving coding for screening and complications; William Larson, Marjorie Baldo, and Marilu Hu of the Centers for Medicare and Medicaid Services (CMS) for providing CMS cost data; Chuck Shih of the Agency of Healthcare Research and Quality for interpreting the CMS cost data; William Lawrence, MD and Kim Wittenberg, MA of AHRQ for contextual and administrative assistance, respectively; and Eric (Rocky) Feuer, PhD of the NCI for continued support of the work and infrastructure of the CISNET consortium.

Appendix 2. Comparison of the MISCAN and SimCRC models on natural history outcomes

Adenoma prevalence, age 65: 39.8%Adenoma prevalence, age 65: 37.1%
Number of adenomas per 1000 by site and size, age 65Number of adenomas per 1000 by site and size, age 65
Proximal colon121.269.961.8Proximal colon171.8185.823.9
Distal colon134.477.468.4Distal colon123.918.341.4
Distribution of adenomas by site and size, age 65 (%)Distribution of adenomas by site and size, age 65 (%)
Proximal colon159831Proximal colon2831463
Distal colon1710835Distal colon203730
CRC incidence among cancer-free 65-year-old population, %CRC incidence among cancer-free 65-year-old population, %
Stage 1Stage 2Stage 3Stage 4TotalStage 1Stage 2Stage 3Stage 4Total

Appendix 3. Discounted costs and discounted life-years gained per 1000 65-year-olds without colorectal cancer screening and with 18 colorectal cancer screening strategies and associated incremental cost-effectiveness ratios

StrategyDiscounted costs ($)Discounted LYGCER ($)ICER ($)Discounted costs ($)Discounted LYGCER ($)ICER ($)
No Screening2,714,6000NAd2,295,6000NAd
HS (3y) + SIGB2,798,15683.11,006d2,106,64677.9CSd
HS (3y) + SIG2,857,19183.71,704d2,143,22577.0CSd
IFOBT (3y) + SIGB2,932,67682.92,631d2,148,70377.5CSd
IFOBT (3y) + SIG2,912,34983.62,367d2,187,27176.6CSd
HII + SIGB2,793,80084.194120,8002,127,30079.0CSd
HII + SIG2,840,50084.61,488d2,113,60080.2CS8,600
HS + SIGB2,863,80087.11,71423,9002,187,80084.7CSd
HS + SIG2,909,40087.12,237d2,187,00085.2CS14,600
IFOBT + SIGB3,025,60087.13,569d2,282,40084.6CSd
IFOBT + SIG2,992,80087.23,190924,8002,283,00085.1CSd
Stool DNA (3y)*3,673,50068.014,105d3,081,30064.212,233d
Stool DNA (5y)*3,383,00058.811,375d2,814,30051.410,089d

LYG = life-years gained vs. no screening; ICER = incremental cost-effectiveness ratio; CER = cost-effectiveness ratio compared with no screening; HII = annual Hemoccult II, HS = annual Hemoccult SENSA; IFOBT = annual immunochemical fecal occult blood test; SIG = 5-yearly sigmoidoscopy without biopsy; SIGB = 5-yearly sigmoidoscopy with biopsy; HS (3y) = 3-yearly Hemoccult SENSA; iFOBT (3y) = 3-yearly immunochemical fecal occult blood test; COL = 10-yearly colonoscopy; d = dominated; --- indicates default strategy (i.e., the least costly and least effective non-dominated strategy); NA = not applicable

*The two stool DNA strategies are not competing options. They are shown here together for comparison purposes only. The ICERs are assessed separately using each stool DNA strategy in turn.


None of the investigators has any affiliations or financial involvements related to the material presented in this manuscript.


1. Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008;149(7):441–50. W81. [PubMed]
2. Itzkowitz S, Brand R, Jandorf L, Durkee K, Millholland J, Rabeneck L, et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol. 2008;103(11):2862–70. [PubMed]
3. Chung DC. Stool DNA testing and colon cancer prevention: another step forward. Ann Intern Med. 2008;149(7):509–10. [PubMed]
4. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. Jama. 2000;284(15):1954–61. [PubMed]
5. Knudsen A. PhD dissertation. Harvard University; 2005. Explaining secular trends in colorectal cancer incidence and mortality with an empirically-calibrated microsimulation model.
6. Loeve F, Boer R, van Oortmarssen GJ, van Ballegooijen M, Habbema JD. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res. 1999;32(1):13–33. [PubMed]
7. Loeve F, Brown ML, Boer R, van Ballegooijen M, van Oortmarssen GJ, Habbema JD. Endoscopic colorectal cancer screening: a cost-saving analysis [see comments] J Natl Cancer Inst. 2000;92(7):557–63. [PubMed]
8. Arminski TC, McLean DW. Incidence and Distribution of Adenomatous Polyps of the Colon and Rectum Based on 1,000 Autopsy Examinations. Dis Colon Rectum. 1964;7:249–61. [PubMed]
9. Blatt L. Polyps of the Colon and Rectum: Incidence and Distribution. Dis Colon Rectum. 1961;4:277–282.
10. Bombi JA. Polyps of the colon in Barcelona, Spain. An autopsy study. Cancer. 1988;61(7):1472–6. [PubMed]
11. Chapman I. Adenomatous polypi of large intestine: incidence and distribution. Ann Surg. 1963;157:223–6. [PubMed]
12. Clark JC, Collan Y, Eide TJ, Esteve J, Ewen S, Gibbs NM, et al. Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. Int J Cancer. 1985;36(2):179–86. [PubMed]
13. Eide TJ. Risk of colorectal cancer in adenoma-bearing individuals within a defined population. Int J Cancer. 1986;38:173–176. [PubMed]
14. Jass JR, Young PJ, Robinson EM. Predictors of presence, multiplicity, size and dysplasia of colorectal adenomas. A necropsy study in New Zealand. Gut. 1992;33(11):1508–14. [PMC free article] [PubMed]
15. Johannsen LG, Momsen O, Jacobsen NO. Polyps of the large intestine in Aarhus, Denmark. An autopsy study. Scand J Gastroenterol. 1989;24(7):799–806. [PubMed]
16. Rickert RR, Auerbach O, Garfinkel L, Hammond EC, Frasca JM. Adenomatous lesions of the large bowel: an autopsy survey. Cancer. 1979;43(5):1847–57. [PubMed]
17. Vatn MH, Stalsberg H. The prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer. 1982;49(4):819–25. [PubMed]
18. Williams AR, Balasooriya BA, Day DW. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut. 1982;23(10):835–42. [PMC free article] [PubMed]
19. Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 9 Regs Public Use. Nov 2003 Sub (1973–2001), DCCPS, Surveillance Research Program, Cancer Statistics Branch. Based on the November 2003 submission. Bethesda, MD: National Cancer Institute; Apr, 2004. [accessed March 5, 2010]. Available from:
20. Lansdorp-Vogelaar I, van Ballegooijen M, Boer R, Zauber A, Habbema JD. A novel hypothesis on the sensitivity of the fecal occult blood test: Results of a joint analysis of 3 randomized controlled trials. Cancer. 2009;115(11):2410–9. [PMC free article] [PubMed]
21. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343(22):1603–7. [PubMed]
22. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999;91(5):434–7. [PubMed]
23. Colorectal cancer screening tests: Conditions for and limitations on coverage. In: 62 Federal Register 59100; Oct. 31, 1997, as amended at 66 FR 55329, Nov. 1, 2001; 67 FR 80040, Dec. 31, 2002.
24. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134(5):1570–95. [PubMed]
25. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin. 2006;56(1):11–25. quiz 49–50. [PubMed]
26. U. S. Preventive Services Task Force. Screening for Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2008;149(9) [PubMed]
27. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology. 2003;124(2):544–60. [PubMed]
28. Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O’Brien MJ, Levin B, et al. Guidelines for Colonoscopy Surveillance After Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology. 2006;130(6):1872–85. [PubMed]
29. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004;351(26):2704–14. [PubMed]
30. Syngal S, Stoffel E, Chung D, Willett C, Schoetz D, Schroy P, et al. Detection of stool DNA mutations before and after treatment of colorectal neoplasia. Cancer. 2006;106(2):277–83. [PubMed]
31. Tagore KS, Lawson MJ, Yucaitis JA, Gage R, Orr T, Shuber AP, et al. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer. 2003;3(1):47–53. [PubMed]
32. Whitney D, Skoletsky J, Moore K, Boynton K, Kann L, Brand R, et al. Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test. J Mol Diagn. 2004;6(4):386–95. [PubMed]
33. Perrone M. Business News 2007. Associated Press Financial Wire; Aug 2, 2007. Government officials will consider paying for Exact Sciences colon cancer screening test.
34. van Ballegooijen M, Habbema JDF, Boer R, Zauber AG, Brown ML. [accessed November 5, 2008];Report to the Agency for Healthcare Research and Quality: a comparison of the cost-effectiveness of fecal occult blood tests with different test characteristics in the context of annual screening in the Medicare population. 2003 Available from:
35. Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007;99(19):1462–70. [PubMed]
36. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Sakaguchi K, et al. Sensitivity of immunochemical fecal occult blood test to small colorectal adenomas. Am J Gastroenterol. 2007;102(10):2259–64. [PubMed]
37. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology. 2005;129(2):422–8. [PubMed]
38. van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol. 2006;101(2):343–50. [PubMed]
39. Itzkowitz SH, Jandorf L, Brand R, Rabeneck L, Schroy PC, 3rd, Sontag S, et al. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol. 2007;5(1):111–7. [PubMed]
40. Levin TR, Conell C, Shapiro JA, Chazan SG, Nadel MR, Selby JV. Complications of screening flexible sigmoidoscopy. Gastroenterology. 2002;123(6):1786–92. [PubMed]
41. Levin TR, Zhao W, Conell C, Seeff LC, Manninen DL, Shapiro JA, et al. Complications of colonoscopy in an integrated health care delivery system. Ann Intern Med. 2006;145(12):880–6. [PubMed]
42. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med. 2000;343(3):162–8. [PubMed]
43. Pox C, Schmiegel W, Classen M. Current status of screening colonoscopy in Europe and in the United States. Endoscopy. 2007;39(2):168–73. [PubMed]
44. Regula J, Rupinski M, Kraszewska E, Polkowski M, Pachlewski J, Orlowska J, et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med. 2006;355(18):1863–72. [PubMed]
45. Warren JL, Klabunde CN, Mariotto AB, Meekins A, Topor M, Brown ML, et al. Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med. 2009;150(12):849–57. W152. [PubMed]
46. Zauber A, Lansdorp-Vogelaar I, Wilschut J, Knudsen AB, van Ballegooijen M, Kuntz KM. [accessed March 5, 2010];Cost-effectiveness of DNA stool testing to screen for colorectal cancer: Report to AHRQ and CMS from the Cancer Intervention and Surveillance Modeling Network (CISNET) for MISCAN and SimCRC Models. 2007 Available from:
47. Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100(9):630–41. [PubMed]
48. Gold M, Siegel JE, Russell LB, Weinstein MG, editors. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
49. Shapiro JA, Seeff LC, Thompson TD, Nadel MR, Klabunde CN, Vernon SW. Colorectal cancer test use from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2008;17(7):1623–30. [PubMed]
50. Mark DH. Visualizing cost-effectiveness analysis. Jama. 2002;287(18):2428–9. [PubMed]
51. Schroy PC, 3rd, Heeren TC. Patient perceptions of stool-based DNA testing for colorectal cancer screening. Am J Prev Med. 2005;28(2):208–14. [PubMed]
52. Schroy PC, 3rd, Lal S, Glick JT, Robinson PA, Zamor P, Heeren TC. Patient preferences for colorectal cancer screening: how does stool DNA testing fare? Am J Manag Care. 2007;13(7):393–400. [PubMed]
53. Exact Sciences Corp. [accessed May 26, 2010];EXACT SCIENCES CORPORATION ANNUAL REPORT ON FORM 10-K. 2010 Available from:
54. U.S. Census Bureau. [accessed May 26, 2010];US Population Projections. Available from:
55. Song K, Fendrick AM, Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology. 2004;126(5):1270–9. [PubMed]
56. Wu GH, Wang YM, Yen AM, Wong JM, Lai HC, Warwick J, et al. Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries. BMC Cancer. 2006;6:136. [PMC free article] [PubMed]
57. O’Brien MJ, Winawer SJ, Zauber AG, Gottlieb LS, Sternberg SS, Diaz B, et al. The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology. 1990;98(2):371–9. [PubMed]
58. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50(1):113–30. [PubMed]